Industry Partnership on EMERPHED™ (Ephedrine Sulfate) Study Bolsters Opportunity for Research and Education
Milwaukee, June 21, 2021 – The Medical College of Wisconsin (MCW) School of Pharmacy partnered with Nexus Pharmaceuticals, Inc. for a pharmaceutical clinical-use study to compare the use of EMERPHED™, a ready-to-use (RTU) ephedrine sulfate product, to the commercially-used concentrated ephedrine sulfate in a simulated operating room setting using MCW’s Standardized Teaching Assessment Resources (STAR) Center. The STAR Center provides a controlled environment where students and healthcare professionals can practice clinical skills using medical simulators in a realistic clinical environment.
MCW and Nexus Pharmaceuticals, Inc. are proud and honored to announce that this clinical-use study was published this month in the highly-regarded Journal of Pharmaceutical Science and Technology, a Science Publishing Group bi-monthly peer-reviewed international open access journal focused on the advancement of scientific research concerning different areas of drug design and delivery sciences and technology.
This novel study combines a sterile compounding lab and a clinical simulation setting to compare different commercially available pharmaceutical products. Unique studies such as this that are conducted in a simulated setting are greatly beneficial to healthcare providers as they allow for a cost-efficient opportunity to evaluate pharmaceutical products without causing risk to patients.
“The MCW School of Pharmacy has access to innovative facilities such as the state-of-the-art STAR simulation center and our own sterile compounding lab which allows us to apply our academic expertise in comparing and evaluating compounding efficacy of medications,” said Abhay Singh Chauhan, PhD, MPharm, BPharm, associate professor of biopharmaceutical sciences at the MCW School of Pharmacy and principal investigator of the study. “Partnerships such as our collaboration with Nexus are instrumental as they allow our students the opportunity to participate in industrial pharmacy research.”
“Nexus Pharmaceuticals is very pleased with the results of the study conducted with the help of the Medical College of Wisconsin,” said Usman Ahmed, chief operating officer of Nexus Pharmaceuticals, Inc. “The results reaffirm EMERPHED™ as a safe, reliable, and accurate alternative to diluting concentrated ephedrine in the OR setting.”
The full results of the study can be read here: https://link.edgepilot.com/s/3bb51702/mmTJ8jIpI06_X18qNyxvoA?u=http://www.sciencepublishinggroup.com/journal/paperinfo?journalid=515%26doi=10.11648/j.pst.20210501.14
# # #
About the Medical College of Wisconsin
With a history dating back to 1893, The Medical College of Wisconsin is dedicated to leadership and excellence in education, patient care, research and community engagement. More than 1,400 students are enrolled in MCW’s medical school and graduate school programs in Milwaukee, Green Bay and Central Wisconsin. MCW’s School of Pharmacy opened in 2017. A major national research center, MCW is the largest research institution in the Milwaukee metro area and second largest in Wisconsin. In the last ten years, faculty received more than $1.5 billion in external support for research, teaching, training and related purposes. This total includes highly competitive research and training awards from the National Institutes of Health (NIH). Annually, MCW faculty direct or collaborate on more than 3,100 research studies, including clinical trials. Additionally, more than 1,600 physicians provide care in virtually every specialty of medicine for more than 2.8 million patients annually.
About Nexus Pharmaceuticals Inc.
Nexus Pharmaceuticals Inc. is a US-based healthcare company and certified diverse supplier, specializing in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor intensive, and more streamlined in practice. Nexus ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they’re needed most. This summer, Nexus is opening a state-of-the art manufacturing facility in Pleasant Prairie, Wisconsin – the first project of its kind in 30 years. For more information visit www.nexuspharma.net/project-tomorrow/.
¥ Hertig J, Degnan D, Scott C, et al. A comparison of error rates between intravenous push methods: a prospective, multisite, observational study. J Patient Saf. 2018;14(1):60-65.
